Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248808225> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4248808225 endingPage "16" @default.
- W4248808225 startingPage "8" @default.
- W4248808225 abstract "The maximum tolerated dose of the multitargeted antifolate drug pemetrexed is 600 mg/m(2) every 3 weeks in heavily pretreated patients without folic acid supplementation. However, with folic acid supplementation, higher doses have been given without limiting side effects. The dose-limiting toxicities of pemetrexed are neutropenia, asthenia, and thrombocytopenia. Other adverse effects include anemia, anorexia, rash, nausea, vomiting, peripheral edema, diarrhea, mucositis, and reversible elevations of transaminase and creatinine levels. Multiple pemetrexed combination phase I trials have been completed or are underway. Without folic acid supplementation, pemetrexed doses of 400 to 600 mg/m(2)could be safely administered with full therapeutic doses of irinotecan, gemcitabine, cisplatin, carboplatin, oxaliplatin, and 5-fluorouracil. Preliminary data from other ongoing trials (with folic acid and vitamin B(12) supplementation) have similarly shown that pemetrexed doses of at least 400 to 500 mg/m(2) can be safely administered with therapeutic doses of vinorelbine, docetaxel, and paclitaxel. Combination studies of pemetrexed with agents active in breast cancer (doxorubicin, epirubicin, and cyclophosphamide) and chest radiotherapy are also now underway. Adverse effects of these combinations have included neutropenia, anemia, thrombocytopenia, asthenia, vomiting, diarrhea, rash, nausea, anorexia, mucositis, and reversible transaminase elevation. The phase I trials of pemetrexed have consistently shown activity against a broad range of tumor types, including colorectal cancer, pancreatic cancer, breast cancer, non-small cell lung cancer, and mesothelioma. This activity has been noted not only in the combination trials, but when pemetrexed is given as a single agent as well. Pemetrexed is a promising drug. It is active against a broad range of cancers, and it has manageable side effects that seem to be lessened with folic acid and vitamin B(12) supplementation." @default.
- W4248808225 created "2022-05-12" @default.
- W4248808225 creator A5009466654 @default.
- W4248808225 creator A5062933842 @default.
- W4248808225 date "2002-04-01" @default.
- W4248808225 modified "2023-09-30" @default.
- W4248808225 title "Phase I trials of pemetrexed" @default.
- W4248808225 doi "https://doi.org/10.1053/sonc.2002.30764" @default.
- W4248808225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12023787" @default.
- W4248808225 hasPublicationYear "2002" @default.
- W4248808225 type Work @default.
- W4248808225 citedByCount "14" @default.
- W4248808225 countsByYear W42488082252012 @default.
- W4248808225 countsByYear W42488082252015 @default.
- W4248808225 crossrefType "journal-article" @default.
- W4248808225 hasAuthorship W4248808225A5009466654 @default.
- W4248808225 hasAuthorship W4248808225A5062933842 @default.
- W4248808225 hasConcept C126322002 @default.
- W4248808225 hasConcept C143998085 @default.
- W4248808225 hasConcept C197934379 @default.
- W4248808225 hasConcept C2776256026 @default.
- W4248808225 hasConcept C2776694085 @default.
- W4248808225 hasConcept C2777063308 @default.
- W4248808225 hasConcept C2777240266 @default.
- W4248808225 hasConcept C2778239845 @default.
- W4248808225 hasConcept C2778248108 @default.
- W4248808225 hasConcept C2778496288 @default.
- W4248808225 hasConcept C2778570526 @default.
- W4248808225 hasConcept C2780580376 @default.
- W4248808225 hasConcept C71924100 @default.
- W4248808225 hasConcept C90924648 @default.
- W4248808225 hasConcept C98274493 @default.
- W4248808225 hasConceptScore W4248808225C126322002 @default.
- W4248808225 hasConceptScore W4248808225C143998085 @default.
- W4248808225 hasConceptScore W4248808225C197934379 @default.
- W4248808225 hasConceptScore W4248808225C2776256026 @default.
- W4248808225 hasConceptScore W4248808225C2776694085 @default.
- W4248808225 hasConceptScore W4248808225C2777063308 @default.
- W4248808225 hasConceptScore W4248808225C2777240266 @default.
- W4248808225 hasConceptScore W4248808225C2778239845 @default.
- W4248808225 hasConceptScore W4248808225C2778248108 @default.
- W4248808225 hasConceptScore W4248808225C2778496288 @default.
- W4248808225 hasConceptScore W4248808225C2778570526 @default.
- W4248808225 hasConceptScore W4248808225C2780580376 @default.
- W4248808225 hasConceptScore W4248808225C71924100 @default.
- W4248808225 hasConceptScore W4248808225C90924648 @default.
- W4248808225 hasConceptScore W4248808225C98274493 @default.
- W4248808225 hasIssue "2 Suppl 5" @default.
- W4248808225 hasLocation W42488082251 @default.
- W4248808225 hasLocation W42488082252 @default.
- W4248808225 hasOpenAccess W4248808225 @default.
- W4248808225 hasPrimaryLocation W42488082251 @default.
- W4248808225 hasRelatedWork W1541193958 @default.
- W4248808225 hasRelatedWork W2243375749 @default.
- W4248808225 hasRelatedWork W2258091149 @default.
- W4248808225 hasRelatedWork W2349278321 @default.
- W4248808225 hasRelatedWork W2358450743 @default.
- W4248808225 hasRelatedWork W2768988395 @default.
- W4248808225 hasRelatedWork W3011176692 @default.
- W4248808225 hasRelatedWork W3029430426 @default.
- W4248808225 hasRelatedWork W3032130105 @default.
- W4248808225 hasRelatedWork W4254666574 @default.
- W4248808225 hasVolume "29" @default.
- W4248808225 isParatext "false" @default.
- W4248808225 isRetracted "false" @default.
- W4248808225 workType "article" @default.